Olivier Morand

Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry Disease on Enzyme Replacement

Nicolas Guérard, Daniel Oder, Peter Nordbeck et al. · Clinical Pharmacology & Therapeutics · 2017 · 106 citations

Plasma Lysosphingomyelin Demonstrates Great Potential as a Diagnostic Biomarker for Niemann-Pick Disease Type C in a Retrospective Study

Richard W.D. Welford, Marco Garzotti, Charles Marques Lourenço et al. · PLoS ONE · 2014 · 93 citations · Full text

Creutzfeldt-jakob Disease, Neurological Disorder, Clinical Neurology +23

Enhanced Synthesis of the Oxysterol 24( <i>S</i> ),25-Epoxycholesterol in Macrophages by Inhibitors of 2,3-Oxidosqualene:Lanosterol Cyclase

Andrea H. Rowe, Carmen Argmann, Jane Y. Edwards et al. · Circulation Research · 2003 · 88 citations

Transport of fluorescent derivatives of fatty acids into cultured human leukemic myeloid cells and their subsequent metabolic utilization

Olivier Morand, Eitan Fibach, Arie Dagan et al. · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · 1982 · 66 citations

Lipid Analysis, Subsequent Metabolic Utilization, Fluorescent Derivatives +8

Long‐term survival outcomes of patients with <scp>Niemann‐Pick</scp> disease type C receiving miglustat treatment: A large retrospective observational study

Marc C. Patterson, William S. Garver, R. Giugliani et al. · Journal of Inherited Metabolic Disease · 2020 · 64 citations · Full text